The Almagest | InterMune's drug delays lung disease progression in trial Reuters UK The drug is already approved to treat IPF in Europe and Canada, where it is marketed as Esbriet. It is also approved in Japan, South Korea, China, India, Argentina and Mexico. IPF is an irreversible condition that leads to progressive loss of lung ... InterMune Reports Phase 3 ASCEND Trial Results of Pirfenidone in Idiopathic ... |
